...
首页> 外文期刊>Radiation Oncology Journal >Results of Hyperfractionated Radiation Therapy in Bulky Stage Ib, IIa, and IIb Uterine Cervical Cancer
【24h】

Results of Hyperfractionated Radiation Therapy in Bulky Stage Ib, IIa, and IIb Uterine Cervical Cancer

机译:超大型放射治疗在Ib,IIa和IIb级子宫宫颈癌中的结果

获取原文
           

摘要

PURPOSE: To evaluate the efficacy of hyperfractionated radiation therapy in carcinoma of the cervix, especially on huge exophytic and endophytic stage Ib, IIa and IIb. METHODS AND MATERIAl: Fourty one patients with carcinoma of the cervix treated with hyperfractionated radiation therapy at the Department of Therapeutic Radiology, Dongsan Hospital, Keimyung University, School of Medicine from Jul, 1991 to Apr, 1994. According to FIGO staging system, there were stage Ib (3 patients), IIa (6 patients) with exophytic (> or = 5cm in diameter) and huge endophytic mass, and IIb (32 patients) with median age of 55 years old. Radiation therapy consisted of hyperfractionated external irradition to the whole pelvis (120cGy/fraction, 2 fraction/day (minimum interval of 6 hours), 3600-5520cGy) and boost parametrial doses (for a total of 4480-6480cGy) with midline shield (4x10cm), and combined with intracavitary irradiation (up to 7480-8520cGy in Ib, IIa and 8480-9980cGy in IIb to point A). The maximum and mean follow up durations were 70 and 47 months respectively. RESULTS: Five year local control rate was 78% and the actuarial overall five year survival rate was 66.1% for all patients, 44.4% for stage Ib, IIa and 71.4% for stage IIb. In bulky IIb (above 5cm in tumor size, 11 patients) five year local control rate and five year survival rate was 88.9%, 73% respectively. Pelvic lymph node status (negative : 74%, positive:25%, P= 0.0015) was significant prognostic factor affecting to five year survival rate. There was marginally significant survival difference by total dose to A point (>84Gy : 70%, ; or =grade 3) and Three patients developed grade 3 gastrointestinal complication. Above grade 3 complication was not noted. There was no treatment related death noted. CONCLUSION: We thought that it may be necessary to increase A point dose to more than 85Gy in hyperfractionated radiotherapy of huge exophytic and endophytic stage Ib,IIa. We considered that hyperfractionated radiation therapy may be tolerable in huge exophytic and endophytic stage IIb cervical carcinoma with acceptable morbidity and possible survival gain but this was results in small patient group and will be confirmed by long term follow up in many patients.
机译:目的:评估超分割放射治疗在子宫颈癌中的疗效,特别是在巨大的外生和内生Ib,IIa和IIb期。方法和材料:1991年7月至1994年4月,在庆明大学医学院附属东山医院放疗科接受超分割放疗的41例宫颈癌患者。根据FIGO分期系统, Ib期(3例),IIa期(6例)具有外生性(直径≥5cm)和巨大的内生肿块,IIb期(32例)中位年龄为55岁。放射治疗包括对整个骨盆进行超分割外部照射(120cGy /部分,每天2次/天(最小间隔为6小时),3600-5520cGy),并采用中线屏蔽(4x10cm)加强宫旁注射剂量(总计4480-6480cGy)。 ),并结合腔内照射(在Ib,IIa中达到7480-8520cGy,在IIb中达到8480-9980cGy到达A点)。最大和平均随访时间分别为70个月和47个月。结果:所有患者的五年局部控制率为78%,精算总体五年存活率为66.1%,Ib,IIa期为44.4%,IIb期为71.4%。在大块的IIb(肿瘤大小超过5cm,11例患者)中,五年局部控制率和五年生存率分别为88.9%和73%。盆腔淋巴结状态(阴性:74%,阳性:25%,P = 0.0015)是影响五年生存率的重要预后因素。总剂量至A点的生存率差异很小(> 84Gy:70%,或= 3级),三名患者发生了3级胃肠道并发症。没有发现3级以上的并发症。没有发现与治疗有关的死亡。结论:我们认为在巨大的外生和内生Ib,IIa期超分割放疗中,有必要将A点剂量增加至85Gy以上。我们认为,超大型放射治疗在巨大的外生性和内生性IIb期宫颈癌中可能是可以耐受的,其发病率可以接受,并且可能获得生存,但这在较小的患者组中是结果,并且将在许多患者中得到长期随访证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号